Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Seres Therapeutics, Inc. (Nasdaq: MCRB), a pioneering company in the field of live biotherapeutics, will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The company's management team is set to deliver a presentation at 3:00 p.m. ET on September 8, 2025. Following the presentation, a webcast replay will be accessible on the Seres website for approximately 21 days.

Founded in Cambridge, Massachusetts, Seres Therapeutics is dedicated to enhancing patient outcomes in vulnerable populations through innovative microbiome-based therapies. Notable for its achievements, the company successfully developed and commercialized VOWST™, which became the first FDA-approved orally administered microbiome therapeutic and was sold to Nestlé Health Science in September 2024.

Currently, Seres is focused on its leading therapeutic candidate, SER-155, which has garnered Breakthrough Therapy designation aimed at reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Additionally, SER-155 has received Fast Track designation for its potential to decrease the risk of infections and graft-versus-host disease in this specific patient population. Results from a Phase 1b clinical trial demonstrated SER-155's effectiveness in significantly reducing bloodstream infections and associated complications compared to placebo.

The company is broadening its pipeline to include SER-155 and other cultivated live biotherapeutics for various medically vulnerable groups beyond allo-HSCT patients, such as those undergoing autologous-HSCT, cancer patients with neutropenia, CAR-T therapy recipients, individuals with chronic liver disease, solid organ transplant recipients, and patients in intensive care units.

For more details, interested parties are encouraged to visit the Seres Therapeutics website or contact their investor relations team.

Seres Therapeutics, Inc. (Nasdaq: MCRB) is poised for a notable presence at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. This event provides an essential platform for the company to showcase its innovative advancements in live biotherapeutics, particularly following its recent achievements.

The approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, represents a significant milestone for Seres. Having sold VOWST to Nestlé Health Science in September 2024, the company has solidified its market credibility and opened new pathways for product development and revenue growth. Investors should closely monitor the performance of Seres during the conference, as management's insights into company strategies, especially concerning SER-155, could influence stock sentiment.

SER-155, which has garnered Breakthrough Therapy and Fast Track designations for specific applications in high-risk patient populations, shows promising clinical trial results, particularly in reducing bloodstream infections during allo-HSCT procedures. Its unique manufacturing process distinguishes it from other therapies, enabling broader application across diverse patient demographics, including those undergoing transplants and patients with chronic diseases.

Given Seres' focus on medically vulnerable populations, and the expansive potential of SER-155 and its pipeline programs, there is an opportunity for growth in untapped markets. Investors should evaluate the upcoming conference presentation for strategic insights into partnerships, clinical updates, or future trials which could catalyze stock movements.

In summary, while Seres Therapeutics presents a compelling investment opportunity due to its innovative pipeline and significant clinical advancements, investors should remain vigilant of market reactions post-conference, as well as broader sector trends impacting biotech valuations. Maintaining a portfolio position in Seres, with an eye on upcoming developments and clinical outcomes, may yield promising returns in the near to mid-term.